Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
50M
-
Number of holders
-
138
-
Total 13F shares, excl. options
-
54.4M
-
Shares change
-
-446K
-
Total reported value, excl. options
-
$616M
-
Value change
-
-$5.35M
-
Put/Call ratio
-
0.09
-
Number of buys
-
83
-
Number of sells
-
-48
-
Price
-
$11.31
Significant Holders of KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) as of Q2 2025
169 filings reported holding KALV - KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share as of Q2 2025.
KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) has 138 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 54.4M shares
.
Largest 10 shareholders include VR ADVISER, LLC (6.73M shares), SUVRETTA CAPITAL MANAGEMENT, LLC (4.96M shares), TANG CAPITAL MANAGEMENT LLC (4.94M shares), Frazier Life Sciences Management, L.P. (4.89M shares), Vestal Point Capital, LP (4.68M shares), Capital World Investors (3.18M shares), BlackRock, Inc. (3.13M shares), VANGUARD GROUP INC (2.41M shares), Woodline Partners LP (1.92M shares), and SILVERARC CAPITAL MANAGEMENT, LLC (1.83M shares).
This table shows the top 138 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.